Preliminary research indicate that {Romlusevimab | BRII-198 | this experimental agent) offers a potential approach for addressing a range of immune-mediated conditions. Targeting {BAFF | B-cell related https://elainezuai475974.blogdigy.com/romlusevimab-brii-198-a-new-possibility-for-chronic-condition-67056506